Updated Daily

TB-500 Research Guide

Thymosin Beta-4's regenerative properties, anti-inflammatory research, and current legal landscape — all in one place.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found throughout the human body. It is most known in athletic and fitness communities for its potential role in accelerating recovery, reducing inflammation, and supporting muscle and tissue healing. Like BPC-157, it is currently restricted but slated for reclassification.

⚖️ Legal & Regulatory Status

Last updated: April 15, 2026

WADA Status
Prohibited in sport
FDA Status
Not approved
Possession
Legal for individuals
Compounding
Category 2 (restricted)

TB-500 is listed on the FDA's Category 2 bulk drug substances list under its full name "Thymosin Beta-4 Fragment," meaning compounding pharmacies cannot legally prepare it for human use at present.

However, TB-500 is included in the February 27, 2026 announcement from HHS Secretary RFK Jr. that 14 Category 2 peptides will be moved back to Category 1. Once the formal FDA rule is published — expected Q2–Q3 2026 — licensed compounding pharmacies will again be able to dispense it under a physician's prescription.

Current status summary:

Important note for athletes: TB-500 and Thymosin Beta-4 are explicitly prohibited by WADA under the S2 category (Peptide Hormones, Growth Factors, Related Substances). Any competitive athlete considering this should understand the anti-doping implications.

🔬 What the Research Says

Last updated: April 15, 2026

TB-500 research is less extensive than BPC-157 but focuses primarily on its role in wound healing, cell migration, and anti-inflammatory activity. The research on full Thymosin Beta-4 (of which TB-500 is the active fragment) is more extensive and informs most of what we know.

Key research findings:

TB-500 vs. Thymosin Beta-4: TB-500 is specifically the Ac-LKKTETQ fragment of Thymosin Beta-4. Most researchers believe this fragment retains the majority of TB-4's biological activity at lower doses. Most preclinical work is done on the full TB-4 molecule; TB-500-specific studies are limited.

Human data: Human trials exist for full Thymosin Beta-4 (RegeneRx Biopharmaceuticals conducted Phase 2 trials for corneal and cardiac indications). Results were mixed — some positive signals in wound healing, less conclusive for cardiac applications.

💬 Community Interest

Last updated: April 15, 2026

TB-500 is heavily discussed in bodybuilding, powerlifting, and endurance sports communities. It is frequently stacked with BPC-157 — the combination is the most commonly discussed peptide protocol for injury recovery online. The theory is that BPC-157 handles local tissue repair while TB-500 provides more systemic anti-inflammatory and healing support.

Athletes with chronic injuries — particularly tendons, ligaments, and overuse injuries — are the core interested group. With the reclassification pending, there is significant anticipation about being able to access TB-500 through legitimate compounding channels for the first time in years.

The WADA prohibition is a recurring topic of concern in communities where competitive athletes participate.

📅 Timeline of Changes

Last updated: April 15, 2026

📄 Download Research Brief

Get a comprehensive, printable summary of TB-500 research, the BPC-157 + TB-500 stacking protocol discussed in the literature, WADA status details, and what reclassification means practically — formatted to bring to a physician.

Deep-dive research brief available

10 pages covering mechanism of action, research findings, dosing protocols, and safety profile.

TB-500 Research Brief $9

Updated whenever significant regulatory or research changes occur. Purchase once, re-download free forever.

PeptideWatch monitors FDA announcements, WADA updates, and medical research daily. This page updates automatically when new information is available. Subscribe to our newsletter to get notified.